PRP vs. SVF in vulvar lichen sclerosus: what the science says

Isolated PRP has not shown benefit over placebo in the treatment of vulvar lichen sclerosus. The most rigorous study available, a randomized controlled trial with 30 women (Goldstein et al., 2019), concluded that PRP did not reduce inflammation compared to the control group. SVF—stromal vascular fraction obtained from the patient’s own fat—does have results published in international scientific journals documenting clinical and histological improvement.

If you have vulvar lichen sclerosus and are researching treatment options, you have likely come across the term PRP: Platelet-Rich Plasma. It is frequently presented as an innovative regenerative therapy for multiple conditions, including yours. The problem is that in the specific case of vulvar lichen sclerosus, scientific evidence does not support that promise when PRP is used in isolation.

This is not an opinion. It is what research published in peer-reviewed journals says. And understanding this can save you time, money, and false hope.

What is PRP and why did it spark interest in lichen sclerosus?

PRP is obtained from the patient’s own blood: it is extracted, centrifuged to concentrate the platelets, and reinjected into the affected area. Platelets contain growth factors, including PDGF, TGF-β, and EGF, which stimulate tissue repair. On paper, this mechanism was attractive for a disease that progressively deteriorates the skin of the vulva.

Early pilot studies, such as the one by Goldstein et al. published in 2017, generated some optimism: a reduction in inflammation was observed in biopsies in nearly 60% of patients. But a pilot study, without a comparison group, has a fundamental limitation: it cannot distinguish whether the improvement is due to the treatment or simply the passage of time.

The trial that changed the argument: Goldstein et al. 2019

Two years later, the same team published a study with greater methodological solidity: randomized, controlled, with 30 women with vulvar lichen sclerosus. This design, called a randomized controlled trial, is the most demanding standard in clinical research because it compares the active treatment directly against a control group, eliminating the placebo effect and observer bias.

The result was clear: PRP did not reduce inflammation compared to the control group. Symptoms did not improve significantly either. The conclusion of the study itself was that PRP cannot be recommended as a first-line treatment for vulvar lichen sclerosus.

This finding does not completely invalidate PRP as an adjuvant in some contexts, but it does close the door to presenting it as an effective treatment when used in isolation. The difference matters, because many patients receive isolated PRP, paying a high price for something that evidence does not support.

What is SVF and how does it differ biologically from PRP?

Stromal Vascular Fraction, or SVF, is a technology distinct in its nature and mechanism of action. It is not obtained from blood, but from the patient’s own fat, through a mechanical digestion process without enzymes. This fraction contains regenerative cells, specifically adipose-derived mesenchymal stem cells, with documented anti-inflammatory and immunomodulatory properties.

The key biological difference is this: PRP provides growth factors. SVF provides living cells with the capacity to act on the underlying inflammatory mechanisms of lichen sclerosus, not just on its superficial consequences.

PRP, by definition, does not contain stem cells. SVF does.

Published evidence on SVF in vulvar lichen sclerosus

Research on SVF in vulvar lichen sclerosus is not experimental in the colloquial sense of the term. There are results published in peer-reviewed international scientific journals.

The research program that led to the Liquenia® Treatment began in 2017 at the La Fe University Hospital in Valencia, in collaboration with the La Fe Health Research Institute (IIS La Fe), under the direction of Dr. Patricia Gutiérrez Ontalvilla. The results have been published in two reference journals:

• Aesthetic Plastic Surgery, 2021 — The randomized controlled study with 19 patients demonstrated the superiority of the protocol compared to conventional treatment with 0.05% clobetasol propionate in symptoms, clinical signs, and histological markers of dermal lesions. DOI: 10.1007/s00266-021-02718-1
• Aesthetic Surgery Journal, 2025 — In 18 women with moderate-severe VLS refractory to conventional treatment, a single session of nanofat + SVF significantly improved itching, burning, pain, and quality of life at 12 months. Biopsies showed reduced fibrosis, decreased CD3+ lymphocytes, and increased vascularization. DOI: 10.1093/asj/sjaf148

In 2025, the protocol was included in the Clinical Practice Guideline of the International Society of Aesthetic Plastic Surgery (ISAPS) for the management of vulvar lichen sclerosus. This is not a commercial recognition: it is the formal evaluation of an international scientific committee. You can consult the full research in the Liquenia scientific evidence section and on the website of the Nixarian Foundation, an entity that promotes research into vulvar lichen sclerosus.

Why this distinction matters to you as a patient

The regenerative therapies market is growing fast, and scientific language is often used imprecisely. “Regenerative” does not equal “effective.” “Cell” does not equal “stem cell.” “Improvement” in a pilot study does not equal “demonstrated benefit over placebo.”

When a patient with vulvar lichen sclerosus seeks alternatives to topical treatment, she deserves accurate information. Not all therapies presented as regenerative have the same backing. The difference between isolated PRP and SVF is not one of degree: it is one of evidence.

Frequently asked questions about PRP and SVF in lichen sclerosus